Psychedelics for Borderline Personality Disorder?

Borderline personality disorder (BPD) is one of the most challenging conditions in psychiatry — both for those who live with it and for the clinicians who treat it. Characterized by intense emotional instability, unstable relationships, chronic feelings of emptiness, impulsivity, and recurrent suicidal ideation, BPD affects an estimated 1.6 to 5.9 percent of the general population. While effective therapies exist, a significant portion of patients remain treatment-resistant, raising the question: could psychedelic-assisted therapies offer a new avenue?

A 2026 narrative review by Artna and colleagues, published in Psychiatry Research, examined 22 studies investigating the effects of ketamine, esketamine, and psilocybin in patients with BPD or BPD features. The findings, while preliminary, are noteworthy.

Why current treatments leave gaps

Dialectical behavior therapy (DBT) remains the gold standard for BPD and has strong evidence for reducing self-harm, suicidal behavior, and emotional dysregulation. But DBT requires sustained engagement over months to years, and many patients either cannot access it, drop out before completing treatment, or continue to experience significant symptoms even after a full course.

Pharmacologically, BPD has no FDA-approved medication. Clinicians often prescribe antidepressants, mood stabilizers, or antipsychotics off-label to manage specific symptom clusters, but the evidence base for these is modest and side effects are common. The biological underpinnings of BPD — which include altered serotonergic signaling, dysregulated glutamate systems, impaired neuroplasticity, and disrupted prefrontal-limbic connectivity — suggest that treatments targeting these pathways could be relevant.

What the review found

Artna and colleagues reviewed the available evidence across three psychedelic compounds:

Ketamine and esketamine had the most data, with several small trials and case series. The findings suggested that subanesthetic ketamine could produce rapid reductions in depressive symptoms and suicidal ideation in patients with BPD — effects that are well-documented in major depressive disorder but had not been systematically examined in BPD populations. Some studies also reported improvements in emotional reactivity and interpersonal functioning, though these outcomes were less consistently measured.

Psilocybin had far fewer studies in BPD specifically, but the available data — primarily from trials that included participants with personality disorder features — suggested that psilocybin-assisted therapy could promote emotional processing, increase psychological flexibility, and enhance therapeutic alliance. These are precisely the domains where BPD patients often struggle most.

Across all compounds, the review found no evidence of increased risk compared to non-BPD populations when treatment was delivered in controlled, supervised settings. This is an important finding given longstanding concerns about using psychedelics in patients with personality pathology.

Ketamine's specific relevance to BPD

Several features of ketamine make it particularly interesting for BPD research:

Rapid reduction of suicidal ideation. Suicidal thoughts and behaviors are central to BPD, and ketamine's ability to rapidly reduce suicidal ideation — often within hours — could fill an urgent clinical need. For patients in crisis, the days-to-weeks onset of conventional medications can be dangerously slow.

Neuroplasticity promotion. BPD is associated with reduced prefrontal cortical volume and impaired connectivity between emotion-regulation regions. Ketamine promotes synaptogenesis and BDNF release, which could theoretically support the neural changes that psychotherapy aims to produce.

Dissociation as both risk and tool. This is where complexity enters. Dissociation is both a therapeutic mechanism of ketamine and a symptom that many BPD patients already experience. The review noted that while dissociative side effects were not more frequent or severe in BPD patients, careful screening and monitoring are essential. Context and supervision matter enormously.

Important caveats

This research is early. The 22 studies reviewed were predominantly small, often lacked BPD-specific outcome measures, and included heterogeneous populations and dosing protocols. No large, randomized, BPD-specific trial of any psychedelic has been completed. The review's authors appropriately call for dedicated RCTs with validated BPD outcome measures before any clinical recommendations can be made.

It is also worth noting that BPD is not currently among the conditions treated at Isha Health. Our clinical practice focuses on depression, anxiety, and PTSD, where the evidence base for ketamine therapy is more established and our outcomes data supports its effectiveness. However, we follow this research closely because advances in our understanding of ketamine's mechanisms in BPD may inform treatment optimization across all conditions.

The bottom line

The Artna review represents the most comprehensive assessment to date of psychedelic therapies for borderline personality disorder. The preliminary signal is encouraging: ketamine, esketamine, and psilocybin appear to be safe in BPD populations and may address core symptoms including emotional dysregulation, suicidal ideation, and impaired neuroplasticity. But "preliminary" is the operative word — much more research is needed before these approaches can be recommended for clinical use in BPD.

For patients with BPD who are interested in these developments, the most productive step today is to ensure access to evidence-based treatments like DBT while staying informed about the evolving research landscape.

Reference: Artna B, et al. "Psychedelic-assisted therapy for borderline personality disorder: a narrative review." Psychiatry Research. 2026.

---

Considering ketamine therapy? Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.